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Matters Arising
SSCP variants in exon 3 in both tumors were identicalLack of BCL10 Mutations in Germ
while exon 1 variants exhibited a complex pattern (Fig-
Cell Tumors and B Cell Lymphomas ure 1A). In order to determine if the SSCP variants repre-
sent somatic mutations or genetic polymorphisms, we
analyzed paired normal-tumor DNAs by SSCP in 14 of
15 exon 1 variants and all 5 exon 3 variants in GCTs.The BCL10 gene has recently been cloned from the
We found identical SSCP variants in all cases, sug-chromosomal translocation t(1;14)(p22;q32) in a low-
gesting that these represent genetic polymorphisms.grade mucosa-associated lymphoid tissue (MALT) lym-
To identify the nature of alterations associated withphoma, and was implicated in the pathogenesis of this
conformation variations, we determined the sequencesand several other tumor types (Willis et al., 1999). BCL10
of 9 exon 3 (paired normal-tumor DNAs in 5 GCTs andis a cellular homolog of the equine herpesvirus-2 E10
4 lymphomas) variants and 12 exon 1 variants (pairedgene, which contains an amino-terminal caspase re-
normal-tumor DNAs in 7 GCTs and 4 lymphomas) (Tablecruitment domain (CARD) and plays a role in apoptosis.
1). We found identical sequences in both normal andWillis et al. (1999) also showed that BCL10 exhibits hy-
tumor DNAs in each case. Although we did not findpermutations in MALT lymphomas with t(1;14) as well
SCCP variants in the 3 GCT cell lines (Tera-1, Tera-2,as frequent mutations in 45% of B and T cell lineage
and GCT-44), we sequenced the exons and found nolymphomas without the 1p22 chromosomal rearrange-
sequence alterations (Figure 1B). This analysis alsoments. In addition, they reported BCL10 mutations in
identified the sequence variation reflected in SSCP vari-cell lines derived from several solid tumor types includ-
ants. The region amplified for exon 1 exhibited 3 differenting three each of male germ cell tumors (GCTs) and
polymorphisms, 2 in the coding region and one in 59
mesotheliomas, suggesting that it may be commonly
intron 1. These included G/T in the first base of codon
involved in the pathogenesis of many human malignan-
5, G/C at the third base of codon 8, and a C/G polymor-
cies. The 1p22 region is affected by frequent deletions phism in intron 1. The polymorphism in exon 3 was
in male GCTs (Mathew et al., 1994) and mesotheliomas G/A at second base of codon 213. Consistent with the
(Lee et al., 1996), suggesting that inactivation of a critical reported high frequency of LOH at the 1p22 region in
gene in this region may play a role in the genesis of GCT, the tumor and the cell line from GCT-240A were
these tumors. reduced to homozygosity at all polymorphic loci in exon
In order to validate a possible role for BCL10 in male 1±intron 1 compared to germline heterozygosity (Figure
GCT and lymphoma pathogenesis, we performed muta- 1B). Thus, these data are at variance with the results
tion analysis of its coding region in a panel of 59 GCTs reported by Willis et al. (1999). The changes noted by
(41 primary tumors and 18 cell lines) (Murty et al., 1994), them, mostly truncations or missense mutations sup-
15 MALT lymphomas, and 15 follicular lymphomas (Offit ported a tumor suppressor gene (TSG) role for BCL10.
et al., 1993). The coding region of BCL10 was amplified Our data contradict this presumption in GCTs and B cell
as described (Willis et al., 1999) and SSCP analysis was lymphomas, and provide evidence for polymorphisms
performed by standard methods (Orita et al., 1989). We in BCL10 coding region.
reasoned that if BCL10 is the target gene deleted, it Lack of mutation in the BCL10 coding region may not
should exhibit mutations in cases with loss of heterozy- exclude it as a deleted TSG. Other genetic or epigenetic
gosity (LOH), and we included 11 such tumors in the mechanisms such as alterations in promoter or methyla-
panel of 41 primary GCTs (Mathew et al., 1994). Among tion patterns can silence gene expression (Baylin et al.,
the cell lines studied, we also included the Tera-1, 1998; Forget, 1998). In order to examine this possibility,
Tera-2, and GCT-44 cell lines studied by Willis et al. we employed a multiplex RT-PCR strategy to analyze
(1999). Conformational changes were noted with high BCL10 expression. This analysis revealed detectable
frequency in both GCTs and lymphomas in exon 1 and levels of expression in 14 of 16 GCTs (10 cell lines and
in 11 cases in exon 3 (5 GCTs and 6 lymphomas) (Table 6 primary tumors) examined. BCL10 message could not
be detected in the remaining 2 cells lines, 577M-F and1). No variants were found in either tumor in exon 2. All
Table 1. Analysis of BCL10 Sequence Alterations in GCT and NHL
Position of Sequence
Variation in cDNA
Tumor Type No. Studied SSCP Variants (amino acid)
Germ cell tumor 59 Exon 1±Intron 1 15 (25.5%) 703 G/T (Ala/Ser)
714 G/C (Leu/Leu)
Intron 1, 58 G/C
Exon 3 5 (8.5%) 1328 G/A (Gly/Glu)
Non-Hodgkin's Lymphoma 30 Exon 1±Intron 1 10 (33.3%) 703 G/T (Ala/Ser)
714 G/C (Leu/Leu)
Intron 1, 58 G/C
Exon 3 6 (20.0%) 1328 G/A (Gly/Glu)
Cell
684
Figure 1. Genetic Analysis of BCL10 in Germ
Cell Tumors (GCTs) and B Cell Lymphomas
(A) PCR-SSCP analysis. (a) and (c), GCT; (b)
and (d), lymphoma. (a) and (b), exon 1; (c) and
(d), exon 3.2. Arrows indicate conformational
changes. N, normal; T, tumor; CL, cell line;
tumor numbers are indicated on top.
(B) PCR sequence analysis. (a) and (b),
Tera-1; (c), GCT-44; (d) and (e), Tera-2; (f),
T-243A; (g)±(i), 240A. Panels (a)±(e) show ab-
sence of mutations in GCT cell lines in relation
to Willis et al. (1999) report, where boxes indi-
cate base change and upward arrow indi-
cates insertion positions. Positions in coding
region of cDNA are: (a), 172 bp; (b), 653 bp;
(c), 172 bp; (d), 58 bp; (e), insertion at 499 bp.
Panel (f), A/G heterozygosity at position 2 of
codon 213. Panels (g)±(i) indicate loss of het-
erozygosity at codon 5 (underlined) in tumor
and cell line 240A. Panel (g), normal DNA;
panel (h), tumor DNA; panel (i) cell line DNA.
The residual peak of G in panel (h) indicates
the presence of contaminating normal cells.
(C) Multiplex RT-PCR analysis of BCL10 ex-
pression in GCT. Primers from the 59 coding
region (59-GGACCCGGAAGAAGCGCCATC
TCC-39 and 59-AAGTAGTCTAACAATTTTCCA
GCCC-39) spanning two different exons were
used to amplify a 249 bp PCR product. PCR
was performed utilizing AmpliTaq DNA poly-
merase (PE Applied Biosystems, Foster City,
CA). The 450 bp PCR product represents
b-actin as control. Marker, PhiX HaeIII; tumor
and cell line numbers are shown on top.
A.B., Reuter, V., and Chaganti, R.S.K. (1994). Oncogene 9, 2245±2102E-R, after 45 cycles of PCR amplification (Figure
2251.1C). Thus, the present analysis rules out a role for BCL10
Offit, K., Parsa, N.Z., Gaidano, G., Filippa, D.A., Louie, D., Pan, D.,as a TSG in the majority of GCTs. On the basis of the
Jhanwar, S.C., Dalla-Favera, R., and Chaganti, R.S.K. (1993). Blooddata presented, we conclude that BCL10 is not a target
82, 2157±2162.
TSG at 1p22 in male GCTs or B cell lymphomas.
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